

CYSTIC FIBROSIS (CF)


Genetics and pathogenesis

- mutations affecting a gene on the long arm of chromosome 7
- the gene codes for a chloride channel known as cystic fibrosis transmembrane conductance regulator (CFTR)
- (CFTR) influences salt and water movement across epithelial cell membranes.
- increased sodium and chloride content in sweat
- increased resorption of sodium and water from respiratory epithelium
- dehydration of the airway epithelium predisposes to chronic bacterial infection and ciliary dysfunction, leading to bronchiectasis.

Cystic fibrosis: basic defect in the pulmonary epithelium







Clinical findings

☐ transport dysfunction: - thick secretions from exocrine glands (lung, pancreas, skin, gonads) - blockage of secretory ducts results in : - severe lung disease - pancreatic insufficiency - azoospermia (Most men with CF are infertile due to failure of development of the vas deferens) presents in childhood with recurrent lung infections that become persistent and chronic lead to bronchiectasis in childhood chronic lung infections • S. Aureus: early • P. aeruginosa: most common • Burkholderia cepacia: worse prognosis but less common • aspergillosis (benign 'colonisers' do not require specific therapy).

Clinical findings

allergic bronchopulmonary aspergillosis

coexistent asthma

Complications of cystic fibrosis

Respiratory

- Infective exacerbations of bronchiectasis
- Spontaneous pneumothorax
- Haemoptysis
- Nasal polyps
- Respiratory failure
- Cor pulmonale
- Lobar collapse due to secretions

Gastrointestinal

- Malabsorption and steatorrhoea
- Distal intestinal obstruction syndrome
- Biliary cirrhosis and portal hypertension
- Gallstones

Others

- Diabetes (25% of adults)
- Delayed puberty
- Male infertility
- Stress incontinence due to repeated forced cough
- Psychosocial problems
- Osteoporosis
- Arthropathy
- Cutaneous vasculitis

Investigations

- ☐ sweat chloride test
 - increased concentrations of sodium, chloride, and potassium > 60 mmol/L is diagnostic in children
 - heterozygotes have normal sweat tests (and no symptoms)
- ☐ PFTs
 - characteristic of obstructive airway disease
 - early: only small airways will be affected
 - later: characteristics of obstructive disease with airflow limitation, hyperinflation, decreased Dco
- ☐ ABGs
 - hypoxemia, hypercapnia later in disease with eventual respiratory failure and cor pulmonale

Investigations

- ☐ CXR
 - hyperinflation
 - increased pulmonary markings
 - bronchiectasis

Treatment

- chest physio and postural drainage
- bronchodilators (ventolin +/- atrovent)
- inhaled DNase (reduces mucus viscosity)
- antibiotics (e.g. ciprofloxacin)
- Regular nebulised antibiotic therapy (colomycin or tobramycin) is used between exacerbations in an attempt to suppress chronic *Pseudomonas* infection.
- lung transplant

Treatments that may reduce chest exacerbations and/or improve lung function in CF

Therapy	Patients treated
Nebulised recombinant human DNase 2.5 mg daily	Age ≥ 5, FVC > 40% predicted
Nebulised tobramycin 300 mg 12-hourly, given in alternate months	Patients colonised with Pseudomonas aeruginosa
Regular oral azithromycin 500 mg three times/week	Patients colonised with Pseudomonas aeruginosa

● DNA ase البشري إرذاذاً لحل الحمض النووي للخلايا الالتهابية المخربة المسؤولة عن لزوجة المفرزات

Treatment of non-respiratory manifestations of CF

Malabsorption:
oral pancreatic enzyme supplements and vitamins.

 Diabetes (25% of patients)often requires insulin therapy

Prognosis

☐ median survival age is 31 years for males and 30.5 for females

death usually due to lung disease (pneumonia, respiratory failure, cor pulmonale)